Syn­cona eyes buy­out of gene ther­a­py biotech Free­line af­ter ear­ly da­ta in two Gauch­er pa­tients

Syn­cona, the ma­jor­i­ty share­hold­er of Free­line Ther­a­peu­tics, has made a bid to ac­quire the biotech less than a month af­ter it re­vealed da­ta from two Gauch­er dis­ease pa­tients in an ear­ly-phase gene ther­a­py study. The to­tal val­ue of the pro­posed ac­qui­si­tion is $24.4 mil­lion, Syn­cona told End­points News in an email.

The in­vest­ment trust co-found­ed Free­line along­side Uni­ver­si­ty Col­lege Lon­don in 2015, with Syn­cona cur­rent­ly own­ing 57.9% of com­pa­ny shares, ac­cord­ing to an SEC fil­ing. But the trust has now placed an of­fer to buy the rest for $5 apiece, ac­cord­ing to an­oth­er SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER